Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Equity Ratio (2020 - 2023)

Cullinan Therapeutics has reported Equity Ratio over the past 4 years, most recently at 0.95 for Q3 2023.

  • Quarterly results put Equity Ratio at 0.95 for Q3 2023, changed 0.2% from a year ago — trailing twelve months through Sep 2023 was 0.95 (changed 0.2% YoY), and the annual figure for FY2022 was 0.95, down 2.0%.
  • Equity Ratio for Q3 2023 was 0.95 at Cullinan Therapeutics, down from 0.96 in the prior quarter.
  • Over the last five years, Equity Ratio for CGEM hit a ceiling of 0.99 in Q2 2021 and a floor of 0.91 in Q2 2022.
  • Median Equity Ratio over the past 4 years was 0.96 (2022), compared with a mean of 0.96.
  • Biggest five-year swings in Equity Ratio: decreased 8.24% in 2022 and later rose 5.62% in 2023.
  • Cullinan Therapeutics' Equity Ratio stood at 0.93 in 2020, then grew by 4.29% to 0.97 in 2021, then fell by 2.0% to 0.95 in 2022, then fell by 0.61% to 0.95 in 2023.
  • The last three reported values for Equity Ratio were 0.95 (Q3 2023), 0.96 (Q2 2023), and 0.94 (Q1 2023) per Business Quant data.